Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT05733611	TitleRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Phase Phase 2	Date Added 2023-02-17	Location	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs	Tags MSS/ MMRp
NCT ID NCT03860272	TitleFc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer	Phase Phase 1	Date Added 2019-03-01	Location Arizona, United States California, United States Colorado, United States Connecticut, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Texas, United States United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Balstilimab, Botensilimab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05973487	TitleA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors	Phase Phase 1	Date Added 2023-08-03	Location Arizona, United States California, United States Connecticut, United States Florida, United States Illinois, United States Kentucky, United States Michigan, United States Minnesota, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05217446	TitleA Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer ( SEAMARK )	Phase Phase 2	Date Added 2022-02-01	Location Arizona, United States California, United States Florida, United States Tennessee, United States Texas, United States Australia Belgium Canada Czechia Denmark France Germany Italy Netherlands Norway Poland Slovakia Spain United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs encorafenib, Braftovi, Erbitux, Keytruda	Tags MSI-H/ MMRd
NCT ID NCT04895722	TitleEvaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)	Phase Phase 2	Date Added 2021-05-20	Location Florida, United States Georgia, United States Illinois, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Belgium Canada Colombia Costa Rica Denmark Estonia France Germany Greece Guatemala Hungary Italy Korea, Republic of Lithuania Netherlands Poland Romania Russian Federation Spain Turkey United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Favezelimab/Pembrolizumab, Pembrolizumab/Quavonlimab, pembrolizumab/vibostolimab coformulation, Keytruda	Tags MSI-H/ MMRd
NCT ID NCT04730544	TitleEfficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE )	Phase Phase 2	Date Added 2021-01-29	Location France	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Ipilimumab, Nivolumab	Tags MSI-H/ MMRd
NCT ID NCT04008030	TitleA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW )	Phase Phase 3	Date Added 2019-07-05	Location California, United States Colorado, United States Illinois, United States New York, United States Oregon, United States Pennsylvania, United States Texas, United States Virginia, United States Argentina Australia Austria Belgium Brazil Canada Chile China Czechia Denmark France Germany Greece Ireland Italy Japan Netherlands Norway Puerto Rico Romania Spain Turkey (Türkiye) United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Bevacizumab, cetuximab, fluorouracil, Irinotecan, Leucovorin, oxaliplatin	Tags MSI-H/ MMRd
NCT ID NCT02997228	TitleCombination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study	Phase Phase 3	Date Added 2016-12-20	Location Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Atezolizumab, fluorouracil, Leucovorin, oxaliplatin	Tags MSI-H/ MMRd
NCT ID NCT06513221	TitleA Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab	Phase	Date Added 2024-07-22	Location	Prior IO Allowed No	CRC-directed Yes	Status	Drugs	Tags MSS/ MMRp

Showing 291 to 299 of 299 entries